"(NASDAQ:EXAS)" was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online.
Exact Sciences Corporation (NASDAQ:EXAS), maintained return on investment for the last twelve months at -54.59, higher than what Reuters data shows regarding industry's average. Comparatively, Exact Sciences Corporation posted earnings of $-0.31 per share in the same quarter past year. Leerink Swann reiterated an outperform rating and issued a $67.00 price target (up from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th.
Sanctuary Wealth Advisors Llc decreased Exact Sciences Corporation (EXAS) stake by 16.05% reported in 2017Q3 SEC filing. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has "Buy" rating given on Wednesday, June 7 by Canaccord Genuity. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.27) by $0.09. EXACT Sciences had a negative return on equity of 24.13% and a negative net margin of 43.01%. The firm had revenue of $87.41 million for the quarter, compared to analysts' expectations of $87.42 million. During the same quarter a year ago, the company posted ($0.34) earnings per share.
A number of other institutional investors have also modified their holdings of EXAS. Robert W. Baird cut shares of EXACT Sciences from an "outperform" rating to a "neutral" rating and set a $56.00 price objective for the company.in a research note on Monday, November 13th. Benchmark set a $65.00 price target on shares of EXACT Sciences and gave the company a "buy" rating in a report on Wednesday, January 17th. BidaskClub raised EXACT Sciences from a "hold" rating to a "buy" rating in a report on Thursday, December 21st. Finally, Zacks Investment Research raised EXACT Sciences from a "hold" rating to a "buy" rating and set a $62.00 price objective on the stock in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. EXACT Sciences presently has a consensus rating of Buy and an average price target of $52.84.
EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Thursday, February 22nd. The stock had a trading volume of 1,383,466 shares, compared to its average volume of 2,870,000. EXACT Sciences has a 52-week low of $19.91 and a 52-week high of $63.60. The stock has a market capitalization of $6.26 Billion however its outstanding shares are 120 Million. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. The shares were sold at an average price of $52.54, for a total value of $87,479.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Graham Peter Lidgard sold 39,884 shares of the firm's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the transaction, the chief operating officer now directly owns 644,621 shares in the company, valued at approximately $27,293,253.14. The disclosure for this sale can be found here. Insiders sold 547,463 shares of company stock worth $27,045,199 over the last 90 days.
A number of large investors have recently added to or reduced their stakes in EXAS. Carillon Tower Advisers Inc. bought a new position in shares of EXACT Sciences during the fourth quarter worth about $66,280,000. Frontier Capital Management Co. Following the completion of the sale, the insider now directly owns 953,564 shares of the company's stock, valued at approximately $50,138,395.12. Victory Capital Management Inc. increased its holdings in EXACT Sciences by 82.9% in the fourth quarter. BlackRock Inc. now owns 7,658,145 shares of the medical research company's stock worth $402,358,000 after buying an additional 126,513 shares during the period. Canada Pension Plan Investment Board lifted its holdings in EXACT Sciences by 95.8% in the 3rd quarter. The stock plunged -2.94 percent over the past quarter, while surged 21.31 percent over the past six months. Green Valley Investors LLC owned 0.77% of EXACT Sciences worth $48,531,000 at the end of the most recent quarter. Institutional investors own 84.88% of the company's stock.
WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and global copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/12/sigma-planning-corp-lowers-stake-in-exact-sciences-co-exas.html. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population.